Portola Pharmaceuticals, Inc. announced that new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, will be presented at the 2019 American Society of Hematology (ASH) Annual Meeting, December 7-10, 2019, in Orlando, Fla. Presentations include an oral session featuring data on cerdulatinib in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), as well as a poster highlighting data in patients with relapsed/refractory follicular lymphoma (FL) receiving cerdulatinib alone or in combination with rituximab. The Company will also present new in vitro data on its Factor Xa inhibitor reversal agent Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo] (USAN: andexanet alfa) related to its effect on thrombin generation in bleeding patients, an in vitro comparison with prothrombin complex concentrates (PCCs), and its effect on modified anti-Factor Xa (FXa) assays in two oral sessions and one poster session, respectively.